Response to letter 'Lymphocyte counts and the risk of COVID-19 in people with MS'

Affiliations

¹ Department of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
² Department of Neurology, Alrijne Hospital, Leiden, The Netherlands.
³ Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.

Comment

Floor C Loonstra et al. Mult Scler. 2021 Sep.

. 2021 Sep;27(10):1626-1627.

doi: 10.1177/1352458520965468. Epub 2020 Oct 16.

¹ Department of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
² Department of Neurology, Alrijne Hospital, Leiden, The Netherlands.
³ Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.

No abstract available

Comment on

Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O. Brownlee W, et al. Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2. Neurology. 2020. PMID: 32241953 No abstract available.
COVID-19 in multiple sclerosis: The Dutch experience.
Loonstra FC, Hoitsma E, van Kempen ZL, Killestein J, Mostert JP. Loonstra FC, et al. Mult Scler. 2020 Sep;26(10):1256-1260. doi: 10.1177/1352458520942198. Epub 2020 Jul 14. Mult Scler. 2020. PMID: 32662742 Free PMC article.
Lymphocyte counts and the risk of COVID-19 in people with MS.
Evangelou N, Garjani A. Evangelou N, et al. Mult Scler. 2021 Sep;27(10):1625-1626. doi: 10.1177/1352458520965460. Epub 2020 Oct 16. Mult Scler. 2021. PMID: 33064054 No abstract available.